Martins André Miguel, Valero Juan Luis Félix, Santos Marlene, Martins João P
LAQV/REQUIMTE, Escola Superior de Saúde, Instituto Politécnico do Porto, Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
Medicina Preventiva y Salud Pública, Facultad de Medicina, Universidad de Salamanca, 37007 Salamanca, Spain.
Vaccines (Basel). 2025 Aug 14;13(8):859. doi: 10.3390/vaccines13080859.
BACKGROUND/OBJECTIVES: Influenza represents a significant burden on global public health, and vaccination is the most effective strategy to reduce it. The large investment in vaccination programs and the need for adjustments in vaccine serotypes are important reasons for evaluating the influenza vaccine's efficacy every year. Establishing a relationship between immunogenicity data and efficacy is also crucial for predicting the efficacy of a vaccine during its development. Antibody response measurement is one of the most common methods for evaluating immunogenicity, particularly in vaccines and biologics. The aim of this systematic review was to define a model that relates the immunogenicity of a given vaccine to its efficacy, based on hemagglutination inhibition titer levels.
To achieve this goal, information was gathered from articles linking immunogenicity with the efficacy of the influenza vaccine in the Medline and Scopus databases. Different mathematical models were developed and applied to assess the relationship between HAI titers and the effectiveness of the flu vaccine. This analysis was conducted for the various existing vaccines, for the different influenza virus strains, and for their efficacy in paediatric populations.
The r obtained ranged from 0.2579 to 0.966, which points to the importance of this immunological factor in the efficacy of the influenza vaccine.
The efficacy values for titer level 40 confirm the validity of the data provided by Hobson.
背景/目的：流感给全球公共卫生带来了重大负担，而接种疫苗是减轻负担的最有效策略。疫苗接种计划的巨额投资以及疫苗血清型调整的必要性是每年评估流感疫苗效力的重要原因。在疫苗研发过程中，建立免疫原性数据与效力之间的关系对于预测疫苗效力也至关重要。抗体反应测量是评估免疫原性最常用的方法之一，尤其是在疫苗和生物制品方面。本系统评价的目的是基于血凝抑制效价水平定义一个将特定疫苗的免疫原性与其效力相关联的模型。
为实现这一目标，从Medline和Scopus数据库中收集了将免疫原性与流感疫苗效力相关联的文章信息。开发并应用了不同的数学模型来评估血凝抑制效价与流感疫苗效力之间的关系。针对各种现有疫苗、不同流感病毒株及其在儿科人群中的效力进行了此项分析。
所得的r值范围为0.2579至0.966，这表明该免疫因素在流感疫苗效力中的重要性。
效价水平为40时的效力值证实了霍布森提供的数据的有效性。
